This week, SumZero is excited to offer our very first corporate access event featuring Ken Londoner, CEO of BioSig Technologies (NASDAQ: BSGM). Londoner is a former buyside investor and entrepreneur, who founded BioSig in 2009 after years of analyzing early-stage growth companies in the medtech space. BioSig has patented its core product, Pure EP™ which provides bioelectronic signal processing technology to hospitals and innovation centers in their treatment of arrythmia. Londoner sheds light on the $5B electrophysiology market, BioSig's strategic partnership with the Mayo Clinic, and the far-reaching software applications for Pure EP™ beyond cardiac ablation.
This week, we sat down with Brian Finn, Founder/PM of FIN Capital who is currently SumZero’s top-ranked contributor. Finn uses his behavioral economics background to weigh the impact of common biases in the public markets. In this episode, Finn introduces us to the concepts of herding, anchoring and recency bias and presents two related case studies: MiMedx and Century Aluminum.
Last week, we discussed the strengths and weaknesses of Bitcoin with crypto funds, Permian Capital Management and WealthMark LLC. Josh Kernan and Ian Del Balso of Permian Capital introduce several other digital assets & technologies including Basic Attention Token (BAT) and the Brave browser, which sits atop the Ethereum blockchain. With over 10M monthly active users, Brave experienced a 19% surge in usership between October and November '19. Next, Ben Esget of WealthMark walks us through the "stock to flow" valuation framework for Bitcoin, citing increasingly low interest rates and the Bitcoin halving process as growth catalysts.
This week, we discuss a Singaporean stock capturing major investor attention, Sea Ltd. and growth opportunities in the online gaming sector. Brian Oh, founder/PM of Saiga Capital, focuses exclusively on gaming equities and shares his macro insights and top picks headed into 2020.
This week, we are joined by Oliver Harris and his team at UK-based Montreux Capital to discuss their specialist healthcare portfolio and the sector-wide implications of Brexit proposals on labor, tax code, and immigration.
Peter Galgay, CIO of Amitell Capital, joins us to take up the other side of the ongoing Burford Capital debate. Galgay and his team have spent years researching litigation finance as an asset class and are invested in a close competitor, IMF Bentham. Galgay draws comparisons between IMF and Burford and outlines investors' discomfort with Burford accounting methods among other insights.
Artem Fokin of Caro-Kann Capital responds publicly to the Muddy Waters case against Burford Capital, as one of the most vocal bulls on the name. He unpacks all salient claims - from accounting irregularities to ethical concerns which have resulted in a 50% price drop since early August.